Cargando…
Overexpression of eis without a mutation in promoter region of amikacin- and kanamycin-resistant Mycobacterium tuberculosis clinical strain
BACKGROUND: Aminoglycosides such as amikacin and kanamycin are effective injectable second-line drugs for treatment of multidrug-resistant tuberculosis. Molecular mechanisms underlying aminoglycoside resistance are not well understood. We have previously identified the amikacin- and kanamycin-resist...
Autores principales: | Sowajassatakul, Angkanang, Prammananan, Therdsak, Chaiprasert, Angkana, Phunpruch, Saranya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047124/ https://www.ncbi.nlm.nih.gov/pubmed/30008266 http://dx.doi.org/10.1186/s12941-018-0285-6 |
Ejemplares similares
-
Draft Genome Sequence of Amikacin- and Kanamycin-Resistant Mycobacterium tuberculosis MT433 without rrs and eis Mutations
por: Sowajassatakul, Angkanang, et al.
Publicado: (2015) -
Molecular characterization of amikacin, kanamycin and capreomycin resistance in M/XDR-TB strains isolated in Thailand
por: Sowajassatakul, Angkanang, et al.
Publicado: (2014) -
Surveillance of pyrazinamide susceptibility among multidrug-resistant Mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand
por: Jonmalung, Jirarut, et al.
Publicado: (2010) -
Correction: Surveillance of pyrazinamide susceptibility among multidrug-resistant Mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand
por: Jonmalung, Jirarut, et al.
Publicado: (2010) -
Intact pks15/1 in Non–W-Beijing Mycobacterium tuberculosis Isolates
por: Chaiprasert, Angkana, et al.
Publicado: (2006)